Traded on the Taipei Exchange (TPEx) as “6942,” the company reports that the DMC shared the interim review of the study indicating the potential for this little-known investigational product. In an Arizona-based, Phase 2, investigator-initiated trial in patients with severe COVID-19 at Banner Health-University Medical Center in Phoenix and Banner Health Medical Center in Tucson, Senhwa Biosciences reports that the study’s Data Monitoring Committee (DMC) indicates positive but interim results.
Recently, a drug development company based in Taipei, Taiwan, and San Diego, California, reported some positive news about their investigational product Silmitasertib-a CK2 inhibitor.
0 kommentar(er)
